Loading...
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial.
Middleton, G Palmer, D Greenhalf, W Ghaneh, P Jackson, R Cox, T Evans, A Shaw, V Wadsley, J Valle, Juan W
Middleton, G
Palmer, D
Greenhalf, W
Ghaneh, P
Jackson, R
Cox, T
Evans, A
Shaw, V
Wadsley, J
Valle, Juan W
Citations
Altmetric:
Abstract
Erlotinib is an EGFR tyrosine kinase inhibitor that has shown a significant but only marginally improved median overall survival when combined with gemcitabine in patients with locally advanced and metastatic pancreatic cancer. Vandetanib is a novel tyrosine kinase inhibitor of VEGFR2, RET, and EGFR, all of which are in involved in the pathogenesis of pancreatic cancer. We investigated the clinical efficacy of vandetanib when used in combination with gemcitabine in patients with advanced pancreatic cancer.
Description
Date
2017-03-01
Publisher
Collections
Keywords
Type
Article
Citation
Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial. 2017 Lancet Oncol